Biovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH Meeting
14:45 EST 4 Dec 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Biovest International, Inc. (OTCQB: “BVTI”), a majority-owned subsidiary
of Accentia Biopharmaceuticals, Inc. (OTCQB: “ABPI”), today announced
that Biovest will present at the Lymphoma Coalition’s annual patient
advoca...
Other Sources for this Article
Biovest International, Inc.
Douglas Calder, 813-864-2558
Vice
President, Strategic Planning & Capital Markets
Email: dwcalder@biovest.com
More From BioPortfolio on "Biovest to Present BiovaxID™ Cancer Vaccine Update at Lymphoma Coalition Patient Advocacy Event prior to ASH Meeting"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
